Publication of a new scientific paper in the peer-reviewed journal "Hepatology Communications"

We’re proud to share our latest research, conducted in collaboration with the Etablissement Français du Sang (EFS), now published in Hepatology Communications! This study showcases the potential of PDC*line, our allogeneic plasmacytoid dendritic cell platform, in identifying novel immunogenic HLA-A*02:01-restricted epitopes associated with hepatocellular carcinoma (HCC) for next-generation immunotherapy development.

Key Highlights:
✅ Identified 16 ectopically expressed genes as potential targets in HCC.
✅ Validated three highly immunogenic epitopes capable of inducing strong CD8+ T-cell responses:

• MAGE-A3 (FLWGPRALV)
• AFP (FMNKFIYEI)
• LRRC46 (KMFHTLDEL)

✅ These tumor-specific epitopes triggered robust T-cell activation, degranulation, and IFN-γ secretion — supporting their promise for cancer vaccines and targeted immunotherapies.

Why It Matters:
Hepatocellular carcinoma is one of the most difficult cancers to treat, with limited response to current therapies. Our findings pave the way for innovative immunotherapies that harness epitope-specific T-cell responses to improve clinical outcomes.

Read the full article here: /article in Hepathology Communications 2025

A big thank you to our collaborators at EFS and the PDC*line Pharma team for their outstanding work and dedication!